Melissa Veenhuizen

Eli Lilly (United States) — United States

Medicine · Health Sciences

14h-index579citations24works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(7), Rheumatoid Arthritis Research and Therapies(6), Chronic Lymphocytic Leukemia Research(5), Veterinary medicine and infectious diseases(5), Systemic Lupus Erythematosus Research(3)

Publications24 total

Interdisciplinary Safety Evaluation for Learning and Decision-Making
Therapeutic Innovation & Regulatory Science·2021· 6 cited
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
RMD Open·2015· 19 citedOpen Access
Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population
JCR Journal of Clinical Rheumatology·2015· 9 cited
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials
Annals of the Rheumatic Diseases·2015· 10 cited
EFFICACY AND SAFETY OF TABALUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM 2 PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIALS
UCL Discovery (University College London)·2015
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study
Annals of the Rheumatic Diseases·2015· 32 cited
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis
Arthritis Research & Therapy·2014· 16 citedOpen Access
FRI0326 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis Who HAD an Inadequate Response to Methotrexate Therapy: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study
Annals of the Rheumatic Diseases·2014
AB0438 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study
Annals of the Rheumatic Diseases·2014· 1 cited
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Annals of the Rheumatic Diseases·2013· 48 citedOpen Access
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
Annals of the Rheumatic Diseases·2012· 73 citedOpen Access
Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability
Current Medical Research and Opinion·2009· 12 cited
Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety.
PubMed·2007· 87 cited
Analysis of reports of human exposure to Micotil 300 (tilmicosin injection)
Journal of the American Veterinary Medical Association·2006· 24 citedOpen Access
Patterns of exposure to <i>Lawsonia intracellularis</i> infection on European pig farms
Veterinary Record·2003· 40 cited
In Vitro Susceptibility of Porcine Respiratory Pathogens to Tilmicosin
Journal of Veterinary Diagnostic Investigation·2000· 25 citedOpen Access
Antimicrobial susceptibility of Mycoplasma hyorhinis
Veterinary Microbiology·2000· 41 cited
I'll Be OK . . . . The Nature of Animal Healing; A Color Handbook of Skin Diseases of the Dog and Cat . . . . Cardiology of the Horse . . . . Georgis' Parasitology for Veterinarians . . . . ECG: Electrocardiography for the Small Animal Practitioner . . . . Healthcare of the Well Pet . . . . Health Maintenance and Principal Microbial Diseases of Cultured Fishes . . . . Introduction to Veterinary Medical Ethics: Theory and Cases . . . . Manual of Equine Dermatology . . . . Atlas of Small Animal Reconstructive Surgery . . . . Equine Surgery . . . . Introduction to Veterinary Pathology . . . . Diseases of Swine . . . . Poisonous Plants: A Veterinary Guide to Toxic Syndromes
Journal of the American Veterinary Medical Association·2000
Evaluating a natural outbreak of porcine proliferative enteropathy and treatment with tylosin in the grow-finish phase
Journal of Swine Health and Production·1998· 14 cited
Oral administration of tylosin phosphate for treatment and prevention of proliferative enteropathy in pigs
American Journal of Veterinary Research·1997· 55 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Pierre‐Yves Berclaz(7), Wendy Komocsar(6), Anne Gill(5), Chin Lee(4), Thomas Dörner(4), Mark C. Genovese(3), Maria Greenwald(2), Julie Satterwhite(2), Li Xie(2), Stephen P Myers(2), Olivier Bénichou(2), S. McOrist(2), Thomas R. Shryock(2), Ronald van Vollenhoven(2), Robert Ortmann(2), G. C. Shurson(2), Joel M. Kremer(2), T. Huizinga(2), David Isenberg(2), Matthew D. Linnik(2)